Digest Network Come funziona
Network
/
Società
Pu
Non verificato

PureTech Health plc

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

63 comunicati stampa

Guarda tutti i comunicati
13/07/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
02/07/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
10/06/2026
Biotecnologia
Salute
Scienza
Farmaceutica
PureTech Health: Results of Annual General Meeting
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
09/06/2026
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
13/05/2026
Industria
Salute
Farmaceutica
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
29/04/2026
Mercato azionario
Web e Social Network
Telefonia e Varie
Tecnica
Medicina - Varie
Software
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
PureTech Announces Annual Results for Year Ended December 31, 2025
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
29/04/2026
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
27/04/2026
Mercato del lavoro
Biotecnologia
Sanità
Salute
Farmaceutica
Medicina - Varie
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
22/04/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0
13/04/2026
Mercato azionario
Finanza
Web e Social Network
Telefonia e Varie
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
PureTech Health: Notice of Results
Fonte
PureTech Health plc
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0